近日,国家药监局药品审评中心(CDE)官网发布,恒瑞医药的瑞维鲁胺(艾瑞恩®)与翰森制药的ADC药物HS-20093联合用药方案,已获CDE批准开展临床试验。引发市场高度关注。图1. 来源于CDE官网据了解,瑞维鲁胺适应症为高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)。前列腺癌症是男性群体中第二大常见肿瘤,当前我国前列腺癌发病率和死亡率均持续升高,且有超过一半的患者在临床首诊即为mHSPC,...
Source Link近日,国家药监局药品审评中心(CDE)官网发布,恒瑞医药的瑞维鲁胺(艾瑞恩®)与翰森制药的ADC药物HS-20093联合用药方案,已获CDE批准开展临床试验。引发市场高度关注。图1. 来源于CDE官网据了解,瑞维鲁胺适应症为高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)。前列腺癌症是男性群体中第二大常见肿瘤,当前我国前列腺癌发病率和死亡率均持续升高,且有超过一半的患者在临床首诊即为mHSPC,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.